Novavax, Inc (NASDAQ:NVAX) price on Thursday, January 16, fall -0.23% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.53.
A look at the stock’s price movement, the close in the last trading session was $8.55, moving within a range at $8.35 and $8.6897. The beta value (5-Year monthly) was 2.088. Turning to its 52-week performance, $23.86 and $3.53 were the 52-week high and 52-week low respectively. Overall, NVAX moved -6.37% over the past month.
Novavax, Inc’s market cap currently stands at around $1.37 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 90.92M for the company’s revenue for the quarter, with a low and high estimate of 83.3M and 103.6M respectively. The average forecast suggests down to a -68.79% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 724.08M, representing a -26.39% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NVAX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 6 analyst(s) rate the stock as a Hold, 10 recommend NVAX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NVAX’s current price about -3.06% and -1.71% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.15, while 7-day volatility ratio is 5.73% and 6.60% in the 30-day chart. Further, Novavax, Inc (NVAX) has a beta value of 2.13, and an average true range (ATR) of 0.65. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $14 and high of $25. Looking at the price targets, the low is -64.13% off current price level while to achieve the yearly target high, price needs to move -193.08%. Nonetheless, investors will most likely welcome a -157.91% jump to $22 which is the analysts’ median price.
If we refocus on Novavax, Inc (NASDAQ:NVAX), historical trading data shows that trading volumes averaged 5.9 over the past 10 days and 5.28 million over the past 3 months. The company’s latest data on shares outstanding shows there are 160.15 million shares.
The 4.49% of Novavax, Inc’s shares are in the hands of company insiders while institutional holders own 59.02% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 36.92 million on 2024-12-31, giving us a short ratio of 10.86. The data shows that as of 2024-12-31 short interest in Novavax, Inc (NVAX) stood at 2874.0 of shares outstanding, with shares short falling to 39.78 million registered in 2024-11-29. Current price change has pushed the stock 6.09% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NVAX stock continues to rise going into the next quarter.
